Ian W Flinn

41PUBLICATIONS
281CO-AUTHORS
Haematological tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Peripheral nervous system
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (41)

|Mar 31, 2026
Lenalidomide plus rituximab for previously untreated advanced follicular lymphoma: the 10-year RELEVANCE trial analysis.

Nicolas Gower, Pierre Feugier, Jason R Westin

|Nov 06, 2025
Addition of Ianalumab (VAY736) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia on Ibrutinib Therapy: Results from a Phase Ib Study.

Kerry A Rogers, Pearlly Yan, Ian W Flinn

|Aug 19, 2025
Zanubrutinib for the treatment of patients with del(17p) and/or TP53 CLL/SLL: analysis across clinical studies.

Constantine S Tam, Mary Ann Anderson, Martin Šimkovič

|May 31, 2025
Zanubrutinib and Venetoclax for Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma With and Without Del(17p)/<i>TP53</i> Mutation: SEQUOIA Arm D Results.

Mazyar Shadman, Talha Munir, Shuo Ma

|May 07, 2025
Zanubrutinib is well tolerated and effective in patients with CLL/SLL intolerant of ibrutinib/acalabrutinib: updated results.

Mazyar Shadman, John M Burke, Jennifer Cultrera

|Apr 10, 2025
ZUMA-8: a phase 1 study of brexucabtagene autoleucel in patients with relapsed/refractory chronic lymphocytic leukemia.

Matthew S Davids, Saad S Kenderian, Ian Flinn

Pageof 7

Frequent Collaborators

9 joint publications

Paolo Ghia

7 joint publications

Mazyar Shadman

6 joint publications

Nancy L Bartlett

5 joint publications

Constantine S Tam